FDA
-
-
-
-
-
-
-
Fate Therapeutics gets FDA clearance for FT839 CAR T-cell candidate
-
-
-
-
-
-
-
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
-
-
-
-
-
-
-
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
-
-
-
-
-
-
-
Fate Therapeutics reports FT819 lupus trial progress at ASH meeting
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis
-
-
-
-
-
-
-
Biotech outlook for 2025: Stifel
-
-
-
-
-
-
-
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
-
330,654 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

